Brainstorm Cell Therapeutics Inc.
Other OTCTotal Valuation
Brainstorm Cell Therapeutics Inc. carries a market capitalization of 8.50M, placing it among publicly traded companies globally. Its enterprise value stands at 11.18M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 8.50M |
| Enterprise Value | 11.18M |
Share Statistics
Brainstorm Cell Therapeutics Inc. currently has 11.03M shares outstanding.
| Shares Outstanding | 11.03M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.04 |
| P/TBV Ratio | -0.88 |
| P/FCF Ratio | -1.46 |
| P/OCF Ratio | -1.46 |
Financial Position
Brainstorm Cell Therapeutics Inc. maintains a current ratio of 0.02, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.02 |
| Quick Ratio | 0.01 |
| Debt / Equity | -13.52 |
| Debt / EBITDA | -0.17 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -442.44 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Brainstorm Cell Therapeutics Inc.'s stock has declined approximately -28.7037% over the past 52 weeks. The 50-day moving average sits at 0.78, while the 200-day moving average is 0.68.
| Beta (5Y) | N/A |
| 52-Week Price Change | -28.7037% |
| 50-Day Moving Average | 0.78 |
| 200-Day Moving Average | 0.68 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -8.73M, while operating income came in at -8.91M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -8.91M |
| Pretax Income | -9.57M |
| Net Income | -9.57M |
| EBITDA | -8.73M |
| EBIT | -8.91M |
| Earnings Per Share (EPS) | -0.94 |
Balance Sheet
Brainstorm Cell Therapeutics Inc. holds 15,000.00 in cash and equivalents against 1.49M in total debt, resulting in a net debt position of 1.31M. Total book value stands at -239.05M, with working capital of -11.58M providing operational flexibility.
| Cash & Cash Equivalents | 15,000.00 |
| Total Debt | 1.49M |
| Net Debt | 1.31M |
| Equity (Book Value) | -239.05M |
| Book Value Per Share | -23.39 |
| Working Capital | -11.58M |
Cash Flow
Brainstorm Cell Therapeutics Inc. produced -6.66M in operating cash flow over the past twelve months.
| Operating Cash Flow | -6.66M |
| Capital Expenditures | N/A |
| Free Cash Flow | -6.66M |
| FCF Per Share | -0.65 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -51.96 |
| FCF Yield | -68.64 |
Stock Splits
Brainstorm Cell Therapeutics Inc.'s most recent stock split took place on October 1, 2024 with a 15:1 split ratio.
| Last Split Date | 10/1/2024 |
| Split Ratio | 15:1 |
Scores
Brainstorm Cell Therapeutics Inc. posts an Altman Z-Score of -500.16, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -500.16 |